These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15534620)

  • 1. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
    Rodrigues P; Hering F; Campagnari JC
    Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
    Heidenreich A; Hofmann R; Engelmann UH
    J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
    Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
    Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
    Vorreuther R; Klotz T; Engelking R
    Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
    Ozyuvaci E; Altan A; Demir C
    Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
    Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
    Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer and bone metastases. The effect of clodronate.
    Kylmälä T
    Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population.
    Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D
    Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
    J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clodronate in the management of bone metastases: a clinical study of 91 patients.
    Serkies K; Jereczek-Fossa B; Badzio A; Jassem J
    Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clodronate for treatment of bone metastases in hormone refractory prostate cancer.
    Hering F; Rodrigues PR; Lipay M
    Int Braz J Urol; 2003; 29(3):228-33. PubMed ID: 15745526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.